Table 2 Lifetime cost-effectiveness results for base case and scenario analyses
Outcomes | Cost ($/ï¿¥) | Effectiveness (QALY or life-years) | ICER | % < 1 time of GDP/capita per QALY | % < 2 times of GDP/capital per QALY | % < 3 times of GDP/capita per QALY | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Enalapril-folic acid | Enalapril | ∆ | Enalapril-folic acid | Enalapril | ∆ | |||||
Base case analyses | ||||||||||
 Quality-adjusted life-year | $3903.69 ￥25,178.80 | $2269.85 ￥14,640.53 | $1633.84 ￥10,538.27 | 11.06 | 11.00 | 0.06 | $26,066.13 ￥168,126.54 | 2.6% | 47.6% | 74.5% |
 Life-year | $3903.69 ￥25,178.80 | $2269.85 ￥14,640.53 | $1633.84 ￥10,538.27 | 22.59 | 22.56 | 0.03 | $61,770.73 ￥398,421.21 | 6.4% | 27.1% | 38.6% |
Scenario analyses | ||||||||||
 Enalapril-folic acid at 1/2 cost | $2788.79 ￥17,987.70 | $2269.85 ￥14,640.53 | $5018.94 ￥3347.16 | 11.06 | 11.00 | 0.06 | $8279.10 ￥53,400.20 | 73.8% | 91.3% | 94.7% |
 Enalapril-folic acid has no benefit beyond year 5 | $4034.69 ￥26,023.75 | $2251.04 ￥14,519.21 | $1783.66 ￥11,504.61 | 11.045 | 11.01 | 0.04 | $45,246.92 ￥291,842.63 | 0 | 9.4% | 32.7% |
 Enalapril-folic acid has no benefit beyond year 10 | $3965.16 ￥25,575.28 | $2247.02 ￥14,493.28 | $1718.15 ￥11,082.07 | 11.06 | 11.01 | 0.05 | $33,012.65 ￥212,931.59 | 0.1% | 29.5% | 59.5% |